David J Byun1,2, Rebecca Braunstein1, Jessica Flynn3, Junting Zheng3, Robert A Lefkowitz4, Sarah Kanbour1, Monica Girotra5,2. 1. Endocrine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Weill Cornell Medical College, New York, NY. 3. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Endocrine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY girotram@mskcc.org.
Abstract
OBJECTIVE: To characterize immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) in a single-institution case series. RESEARCH DESIGN AND METHODS: Retrospective chart review of 18 patients with new-onset ICI-DM following anti-programmed cell death protein 1 (PD-1)/anti-programmed cell death protein ligand 1 (PD-L1) therapy for advanced carcinomas. RESULTS: Of 18 patients, 9 had diabetic ketoacidosis (median glucose 27.92 mmol/L; median glucose before presentation 6.35 mmol/L). Median C-peptide at ICI-DM diagnosis was low, and it declined during follow-up. Median anti-PD-1/anti-PD-L1 duration before ICI-DM was 3.65 months (range 0.56-12.23 months). Time to ICI-DM onset was a median 1.4 months/3 ICI cycles and 6 months/10 cycles in those patients who were positive and negative for GAD65 autoantibodies, respectively. Time to ICI-DM onset was a median 2.5 months/3 ICI cycles and 4.8 months/8 cycles after anti-PD-L1 or anti-PD-1 therapy, respectively. Significant pancreatic atrophy was seen radiographically. CONCLUSIONS: ICI-DM presents abruptly, appears irreversible, is characterized by pancreatic atrophy, and may occur both earlier following PD-L1 blockade compared with PD-1 inhibition and in those who have positive GAD65 autoantibodies.
OBJECTIVE: To characterize immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) in a single-institution case series. RESEARCH DESIGN AND METHODS: Retrospective chart review of 18 patients with new-onset ICI-DM following anti-programmed cell death protein 1 (PD-1)/anti-programmed cell death protein ligand 1 (PD-L1) therapy for advanced carcinomas. RESULTS: Of 18 patients, 9 had diabetic ketoacidosis (median glucose 27.92 mmol/L; median glucose before presentation 6.35 mmol/L). Median C-peptide at ICI-DM diagnosis was low, and it declined during follow-up. Median anti-PD-1/anti-PD-L1 duration before ICI-DM was 3.65 months (range 0.56-12.23 months). Time to ICI-DM onset was a median 1.4 months/3 ICI cycles and 6 months/10 cycles in those patients who were positive and negative for GAD65 autoantibodies, respectively. Time to ICI-DM onset was a median 2.5 months/3 ICI cycles and 4.8 months/8 cycles after anti-PD-L1 or anti-PD-1 therapy, respectively. Significant pancreatic atrophy was seen radiographically. CONCLUSIONS: ICI-DM presents abruptly, appears irreversible, is characterized by pancreatic atrophy, and may occur both earlier following PD-L1 blockade compared with PD-1 inhibition and in those who have positive GAD65 autoantibodies.
Authors: Martha L Campbell-Thompson; Stephanie L Filipp; Joseph R Grajo; Bimota Nambam; Richard Beegle; Erik H Middlebrooks; Matthew J Gurka; Mark A Atkinson; Desmond A Schatz; Michael J Haller Journal: Diabetes Care Date: 2018-12-14 Impact factor: 19.112
Authors: Martha L Campbell-Thompson; John S Kaddis; Clive Wasserfall; Michael J Haller; Alberto Pugliese; Desmond A Schatz; Jonathan J Shuster; Mark A Atkinson Journal: Diabetologia Date: 2015-09-10 Impact factor: 10.122
Authors: Romualdo Barroso-Sousa; William T Barry; Ana C Garrido-Castro; F Stephen Hodi; Le Min; Ian E Krop; Sara M Tolaney Journal: JAMA Oncol Date: 2018-02-01 Impact factor: 31.777
Authors: Angeliki M Stamatouli; Zoe Quandt; Ana Luisa Perdigoto; Pamela L Clark; Harriet Kluger; Sarah A Weiss; Scott Gettinger; Mario Sznol; Arabella Young; Robert Rushakoff; James Lee; Jeffrey A Bluestone; Mark Anderson; Kevan C Herold Journal: Diabetes Date: 2018-06-24 Impact factor: 9.461
Authors: Linda Wu; Venessa H M Tsang; Sarah C Sasson; Alexander M Menzies; Matteo S Carlino; David A Brown; Roderick Clifton-Bligh; Jenny E Gunton Journal: Front Endocrinol (Lausanne) Date: 2021-11-05 Impact factor: 5.555
Authors: Ana Luisa Perdigoto; Songyan Deng; Katherine C Du; Manik Kuchroo; Daniel B Burkhardt; Alexander Tong; Gary Israel; Marie E Robert; Stuart P Weisberg; Nancy Kirkiles-Smith; Angeliki M Stamatouli; Harriet M Kluger; Zoe Quandt; Arabella Young; Mei-Ling Yang; Mark J Mamula; Jordan S Pober; Mark S Anderson; Smita Krishnaswamy; Kevan C Herold Journal: JCI Insight Date: 2022-09-08